Wenle Xia

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Wenle Xia, Robert J. Mullin, Barry R. Keith et al. · Oncogene · 2002 · 669 citations

Medicine, Oncology, Pharmacology +16

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

Wenle Xia, Sarah Bacus, Priti S. Hegde et al. · Proceedings of the National Academy of Sciences · 2006 · 377 citations · Full text

Medicine, Oncology, Pharmacology +17

Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

Neil L. Spector, Wenle Xia, Howard A. Burris et al. · Journal of Clinical Oncology · 2005 · 365 citations · Full text

Medicine, Oncology, Pharmacology +17

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

Wenle Xia, Catherine Gérard, Lei-Hua Liu et al. · Oncogene · 2005 · 262 citations

Medicine, Oncology, Pharmacology +17

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016

Wenle Xia, Lei-Hua Liu, Peter Ho et al. · Oncogene · 2004 · 253 citations

Life Sciences, Molecular Biology, Pharmacology +10